OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial Board	124
Editorial Board	122
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	83
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	77
Editorial Board	75
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	53
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	53
Thiazide-induced hyponatremia	52
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	51
Menopausal hormone therapy for the management of osteoporosis	51
Genetics of pubertal timing	49
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	48
Coronavirus disease 2019 and vitamin D	46
Immune checkpoint inhibitor-related thyroid dysfunction	43
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	42
Regulation of bone mass: A splendid Orchestra	40
The role of androgens in transgender medicine	35
Editorial Board	35
Sexual health and contraception in the menopause journey	34
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Editorial Board	31
Haematological actions of androgens	30
Remnant lipoprotein particles and cardiovascular disease risk	29
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	29
Cardiometabolic outcomes of early onset hypogonadism in males	29

Editorial Board	29
Metabolic complications and their mechanisms in patients with craniopharyngioma	28
Type 1 diabetes related to immune checkpoint inhibitors	27
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	27
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	26
Non-oestrogen-based and complementary therapies for menopause	25
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25
The effect of osteoporosis treatment on bone mass	24
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	24
Medullary thyroid cancer - An update	24
Pathophysiology of thyroid-associated orbitopathy	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Immune checkpoint inhibitor-related hypophysitis	23
Hormone therapy for menopause and premature ovarian insufficiency	23
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	22
History of androgens and androgen action	22
The role of hormone therapy in urogenital health after menopause	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Editorial Board	20
Editorial Board	19
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	19
Localization in primary hyperparathyroidism	19
Safety of androgen therapy in men with prostate cancer	18
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	18
Hyponatraemic encephalopathy	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Editorial Board	18
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	18
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	17
Genotype-phenotype correlations in Graves’ disease	17
Mortality in craniopharyngiomas: Data from the last two decades	17
Editorial Board	17
Diagnostic algorithm of hyponatremia	17
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Genetics of anti-Müllerian hormone and its signaling pathway	16
Care quality improvement in differences of sex development	16
Preface	16
Anaplastic thyroid cancer: An update	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
Hormone replacement in disorders of sex development, and long-term effects	15
Exercise and physical activity in individuals at risk of fracture	15
Chemokines in thyroid autoimmunity	14